← All candidates
114 insider filings on record.
114 filings on record.
PCVXVaxcyte, Inc.
NasdaqGS · Healthcare · $8.80B
$59.54
+0.12% · Sep 14
114 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 34 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$8.80B
Float
136.4M
92% public
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
109 more transactions on Pro →Context
Wall St
$109.00 avg target
+83.1% vs today · 9 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
0 of 4 quarters beat
Q1 '26−$2.30 act−$0.53
Q4 '25−$1.80 act−$0.30
Q3 '25−$1.56 act−$0.32
Q2 '25−$1.22 act−$0.06
Coverage
Vaxcyte (PCVX) Conducts Initial Dosage for VAX-A1 Phase 1 StudyInsider Monkey · 06-17Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial EnrollmentsSimply Wall St. · 06-01Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical TrialsInsider Monkey · 05-29Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.Motley Fool · 06-03
The file stays open
114 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice